Product
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and OverStatus: Completed, Estimated PCD: 2024-04-30